Findings

What do systematic reviews say?

114 questions · 129 findings · 12 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 37 · 28.7%GRADE not reported 4 · 3.1%Very low 24 · 18.6%Low 37 · 28.7%Moderate 20 · 15.5%High 7 · 5.4%

Low molecular weight heparin vs unfractionated heparin

Extracorporeal circuit thrombosis Median · adults with kidney failure treated with long‐term HD

1 finding from 1 review

Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only
1.58 [0.46, 5.42]
3 studies · 91 participants
Low

Low molecular weight heparin vs unfractionated heparin

Major bleeding · adults with kidney failure treated with long‐term HD

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Death (any cause) (median · adults with kidney failure treated with long‐term HD

Low molecular weight heparin showed no clear difference in death (any cause) Median compared with unfractionated heparin (low certainty).

1 finding from 1 review

Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only
RR 2.64 [0.51, 13.83]
3 studies · 120 participants
Low

Low molecular weight heparin vs unfractionated heparin

Dialysis vascular access thrombosis Median · adults with kidney failure treated with long‐term HD

Low molecular weight heparin showed no clear difference in dialysis vascular access thrombosis Median compared with unfractionated heparin (low certainty).

1 finding from 1 review

Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only
RR 0.2 [0.01, 3.7]
2 studies · 45 participants
Low

Low molecular weight heparin vs unfractionated heparin

Dialysis vascular adequacy (Kt/V) · adults with kidney failure treated with long‐term HD

1 finding from 1 review

Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Low molecular weight heparin vs unfractionated heparin

Minor bleeding · adults with kidney failure treated with long‐term HD

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Blood transfusion · adults with kidney failure treated with long‐term HD

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Outcomes · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

All‐cause mortality · patients with cancer with venous thromboembolism

Low molecular weight heparin showed no clear difference in mortality compared with unfractionated heparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 0.66 [0.4, 1.1]
5 studies · 418 participants
Low

Low molecular weight heparin vs unfractionated heparin

Recurrent VTE · patients with cancer with venous thromboembolism

Low molecular weight heparin showed no clear difference in recurrent VTE compared with unfractionated heparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 0.69 [0.27, 1.76]
3 studies · 422 participants
Low

Low molecular weight heparin vs unfractionated heparin

Major bleeding · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Minor bleeding ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Quality of life ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Thrombocytopenia · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin and idraparinux vs usual care

Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs control

CVC‐related thrombosis ( · children with a CVC

Does low molecular weight heparin prevent central venous… showed no clear difference in CVC‐related thrombosis ( compared with control (low certainty).

1 finding from 1 review

Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
RR 0.68 [0.27, 1.75]
2 studies · 787 participants
Low

Low molecular weight heparin vs control

Symptomatic catheter‐related thrombosis (up to 3 months) · children with a CVC

Does low molecular weight heparin prevent central venous… showed no clear difference in symptomatic CVC‐related thrombosis ( compared with control (low certainty).

1 finding from 1 review

Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
RR 1.03 [0.21, 4.93]
1 study · 158 participants
Low

Low molecular weight heparin vs control

Asymptomatic CVC‐related thrombosis ( · children with a CVC

Does low molecular weight heparin prevent central venous… showed no clear difference in asymptomatic CVC‐related thrombosis ( compared with control (low certainty).

1 finding from 1 review

Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
RR 1.17 [0.45, 3.08]
1 study · 158 participants
Low

Low molecular weight heparin vs control

Major bleeding · children with a CVC

Does low molecular weight heparin prevent central venous… showed no clear difference in major bleeding ( compared with control (low certainty).

1 finding from 1 review

Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
RR 0.27 [0.05, 1.67]
2 studies · 813 participants
Low